The Shake It Up Australia Foundation for Parkinson’s Research, together with its partners worldwide, has pledged to cover up to 50% of the costs associated with opening a clinical trial into oral Anavex 2-73 (blarcamesine) as a treatment for Parkinson’s disease. Anavex Life Sciences, the developer of Anavex…
Novant Health announced that it will soon be the first healthcare provider in the Carolinas to offer an incision-free brain “surgery” technique to treat essential tremor and tremors caused by Parkinson’s disease. The technique, called MR-guided focused ultrasound, uses magnetic resonance imaging (MRI) to identify brain…
The small molecule anle138b has shown “excellent” safety and tolerability profiles in a first study in healthy volunteers, and reached therapeutic dose levels in the blood, according to its developer Modag. These results enabled Modag to secure an additional $1.4 million in funding from the Michael J.
Denali Therapeutics announced a partnership with Biogen to jointly develop and advance DNL151, an investigational small molecule treatment for Parkinson’s disease, to late-stage clinical testing following results from ongoing Phase 1/1b trials. The partnership also includes Biogen and Denali working to co-develop and, upon approval, jointly market this and…
The nonprofit Parkinson’s UK announced an additional £1 million (about $1.3 million) award to NRG Therapeutics, advancing its work into potential treatments that can rescue damaged mitochrondria — the cellular component responsible for energy production — in brain cells. This funding is part of a £4 million annual investment…
The Michael J. Fox Foundation (MJFF) has awarded a total of $8.5 million to research teams at AC Immune, Mass General Brigham, and Merck to develop a way to detect the protein alpha-synuclein in the brains of people living with Parkinson’s disease. The three…
Axial Biotherapeutics announced a $440,000 grant from the Michael J. Fox Foundation for Parkinson’s Research to support its efforts to develop a model that can mimic the nervous system of the gastrointestinal tract, and help in evaluating potential Parkinson’s disease treatments. Though Parkinson’s is primarily considered a neurodegenerative disorder,…
The U.S. Food and Drug Administration (FDA) has approved a new app developed by Abbott, called the Patient Controller app, which will allow patients with chronic neurological conditions to manage personalized therapy regimens using compatible smartphones. The Patient Controller app, which is compatible with Apple’s operating system iOS, synchronizes…
Pathogenic bacteria such as Salmonella typhimurium were seen for a first time to form biofilms, or dense clusters of bacteria that can adhere to surfaces and withstand harsh conditions, in the intestines of mice in a study. Salmonella was previously thought to only form biofilms in the environment. These biofilms…
Seelos Therapeutics has begun a preclinical study in rodents to test a gene therapy approach to deliver its investigational candidate SLS-007, a potential treatment for Parkinson’s disease. Results are expected by late this year or early 2021. One hallmark of Parkinson’s disease progression is the formation of…
Get regular updates to your inbox.